Weekly Recap | Upstream Bio -0.72%, most brokers rate it buyWeekly Review·Oct 24, 2026 at 07:12 AMUPB+5.84%
Weekly Recap | Sellas Life Sciences +15.63%, consensus target well above spotWeekly Review·Oct 24, 2026 at 07:01 AMSLS+0.61%
Weekly Recap | Summit Therapeutics +5.74%, ivonescimab data stack upWeekly Review·Oct 24, 2026 at 07:00 AMSMMT-5.46%
